Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...
Internet Union is the first acquisition under AEIF3’s ownership Arcus acquired a majority stake in FixMap in September The transaction will increase FixMap’s portfolio to around 387k homes ...
HAYWARD, Calif., February 18, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...
In this article, we are going to take a look at where Arcus Biosciences, Inc. (NYSE:RCUS) stands against other stocks with at least $10 million in insider spending recently. Since Donald Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback